MedCost Clear Cost calculator

Drugs / Kisunla

Kisunla cost

donanemab-azbt · Eli Lilly. Every official price for Kisunla, side by side, with who pays it.

Short answer

FDA approved Kisunla (donanemab-azbt) on Jul 2, 2024. Eli Lilly lists Kisunla at $731.49 per 350 mg/20 mL vial, as of October 1, 2026 (date of the list price on Lilly's pricing page). Medicare Part B pays up to $4.185 per 2 mg for Kisunla given by IV infusion (October 1, 2026 to December 31, 2026).412

Source: FDA, Eli Lilly and CMS · checked Oct 25, 2026

Kisunla: the official numbers, by situation

PriceAmountWhose price, and who it applies toDate
List price
per 350 mg/20 mL vial
$731.491 Eli Lilly's price to wholesalers (WAC). Most people don't pay it directly. October 1, 2026 (date of the list price on Lilly's pricing page)
Medicare Part B payment limit
per 2 mg, Kisunla given by IV infusion
$4.1852 What Medicare pays when the drug is paid under Part B (for example, given in a clinic). CMS lists Part B coinsurance for this code as 20%. October 1, 2026 – December 31, 2026

None of these is your price at the counter: that depends on how you pay. Details and sources for each number are further down.

FDA approval

Every official price

PriceAmountWhat it isDate
Maker's list price (WAC) $731.491 Per 350 mg/20 mL vial. The price the maker charges wholesalers; most people do not pay it directly. October 1, 2026 (date of the list price on Lilly's pricing page) (checked Oct 25, 2026)
Medicare Part B payment limit
Kisunla given by IV infusion (donanemab-azbt) · HCPCS J0175
$4.1852 Per 2 mg, when given in a clinic or hospital outpatient setting and paid under Part B. CMS lists Part B coinsurance for this code as 20%. October 1, 2026 – December 31, 2026
Pharmacy acquisition cost (NADAC)Not listedThis drug is not in the NADAC survey, which covers drugs dispensed by retail pharmacies.—

These are prices the drug company, Medicare and pharmacies use. What you pay depends on your coverage; see below. CMS notes that a code's presence in its payment file does not by itself mean Medicare covers the drug.3

Kisunla cost per infusion and per year

At Eli Lilly's list price of $731.49 per 350 mg/20 mL vial, a full 1,400 mg dose is $2,925.96, given once every 4 weeks. The first 13 infusions (52 weeks) come to $33,648.54 at list price.16

InfusionDoseVialsList price
Infusion 1350 mg1 × 350 mg$731.49
Infusion 2700 mg2 × 350 mg$1,462.98
Infusion 31,050 mg3 × 350 mg$2,194.47
Infusion 4 and later1,400 mg4 × 350 mg$2,925.96
Maker's list price as of October 1, 2026 (date of the list price on Lilly's pricing page).

The label says to consider stopping when amyloid plaques fall to minimal levels on a PET scan, so the number of infusions differs from person to person.6

With Medicare Part B, the payment limit for a 1,400 mg dose (HCPCS J0175) is $2,929.50; 20% coinsurance on that is $585.90 per infusion, before the Part B deductible and without a Medigap or Medicare Advantage plan.2

List price read on the maker's page Oct 25, 2026. List price is what the maker charges wholesalers, not what you pay. These figures are for the medicine only: the clinic's infusion, MRI and PET charges are extra. Your doctor decides the dose and schedule.

Kisunla vs Leqembi: first-year list price

  • Kisunla: $33,648.54, 13 infusions, one every 4 weeks.
  • Leqembi: $24,984.70, 26 infusions, one every 2 weeks, for a 70 kg (154 lb) person.

Medicine only, at each maker's list price, on the label's starting schedule. A price comparison, not a comparison of how well they work.

With Medicare

With commercial insurance or no insurance

Which drug, which dose, and whether to start, stop or switch are medical decisions. Ask your doctor or pharmacist.

Official sources for this page (6)
  1. “The list price of Kisunla is $731.49 per 350 mg/20 mL vial ... List price, also referred to as wholesale acquisition cost or WAC, is the price at which Lilly sells its products to wholesalers. ... WAC from AnalySource accessed on October 1, 2026.”
  2. “The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate whether Medicare covers a drug.”
  3. “Kisunla donanemab-azbt 7/2/2024 To treat Alzheimer’s disease”
  4. “Effective April 7, 2022, the Centers for Medicare & Medicaid Services (CMS) covers Food and Drug Administration (FDA) approved monoclonal antibodies directed against amyloid for the treatment of AD when furnished in accordance with Section B under coverage with evidence development (CED) for patients who have a clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.”
  5. “Administer KISUNLA as an intravenous infusion over approximately 30 minutes every four weeks as follows ( 2.2 ): Infusion 1: 350 mg Infusion 2: 700 mg Infusion 3: 1,050 mg Infusion 4 and beyond: 1,400 mg Consider stopping dosing with KISUNLA based on reduction of amyloid plaques to minimal levels on amyloid PET imaging.”

Did this page answer your question?